Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Liu S, Chai T, Garcia-Marques F, Yin Q, Hsu EC, Shen M, Shaw Toland AM, Bermudez A, Hartono AB, Massey CF, Lee CS, Zheng L, Baron M, Denning CJ, Aslan M, Nguyen HM, Nolley R, Zoubeidi A, Das M, Kunder CA, Howitt BE, Soh HT, Weissman IL, Liss MA, Chin AI, Brooks JD, Corey E, Pitteri SJ, Huang J, Stoyanova T. UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas. Cell Rep Med. 2024 Feb 20;5(2):101381. doi: 10.1016/j.xcrm.2023.101381. Epub 2024 Jan 19. PubMed PMID: 38244540; PubMed Central PMCID: PMC10897521.
Guimarães CF, Liu S, Wang J, Purcell E, Ozedirne T, Ren T, Aslan M, Yin Q, Reis RL, Stoyanova T, Demirci U. Co-axial hydrogel spinning for facile biofabrication of prostate cancer-like 3D models. Biofabrication. 2024 Feb 20;16(2). doi: 10.1088/1758-5090/ad2535. PubMed PMID: 38306674.
Liu S, Hawley SJ, Kunder CA, Hsu EC, Shen M, Westphalen L, Auman H, Newcomb LF, Lin DW, Nelson PS, Feng Z, Tretiakova MS, True LD, Vakar-Lopez F, Carroll PR, Simko J, Gleave ME, Troyer DA, McKenney JK, Brooks JD, Liss MA, Stoyanova T. High expression of Trop2 is associated with aggressive localized prostate cancer and is a candidate urinary biomarker. Sci Rep. 2024 Jan 4;14(1):486. doi: 10.1038/s41598-023-50215-z. PubMed PMID: 38177207; PubMed Central PMCID: PMC10766957.
Bangayan NJ, Wang L, Burton Sojo G, Noguchi M, Cheng D, Ta L, Gunn D, Mao Z, Liu S, Yin Q, Riedinger M, Li K, Wu AM, Stoyanova T, Witte ON. Dual-inhibitory domain iCARs improve the efficiency of the AND-NOT gate CAR T strategy. Proc Natl Acad Sci U S A. 2023 Nov 21;120(47):e2312374120. doi: 10.1073/pnas.2312374120. Epub 2023 Nov 14. PubMed PMID: 37963244; PubMed Central PMCID: PMC10666036.
Shen M, Liu S, Toland A, Hsu EC, Hartono AB, Alabi BR, Aslan M, Nguyen HM, Sessions CJ, Nolley R, Shi C, Huang J, Brooks JD, Corey E, Stoyanova T. ACAA2 is a novel molecular indicator for cancers with neuroendocrine phenotype. Br J Cancer. 2023 Nov;129(11):1818-1828. doi: 10.1038/s41416-023-02448-y. Epub 2023 Oct 5. PubMed PMID: 37798372; PubMed Central PMCID: PMC10667239.
Garcia-Marques FJ, Zakrasek E, Bermudez A, Polasko AL, Liu S, Stoyanova T, Brooks JD, Lavelle J, Pitteri SJ. Proteomics analysis of urine and catheter-associated biofilms in spinal cord injury patients. Am J Clin Exp Urol. 2023;11(3):206-219. eCollection 2023. PubMed PMID: 37441441; PubMed Central PMCID: PMC10333135.
Wu WE, Chang E, Jin L, Liu S, Huang CH, Kamal R, Liang T, Aissaoui NM, Theruvath AJ, Pisani L, Moseley M, Stoyanova T, Paulmurugan R, Huang J, Mitchell DA, Daldrup-Link HE. Multimodal In Vivo Tracking of Chimeric Antigen Receptor T Cells in Preclinical Glioblastoma Models. Invest Radiol. 2023 Jun 1;58(6):388-395. doi: 10.1097/RLI.0000000000000946. Epub 2022 Dec 21. PubMed PMID: 36729074; PubMed Central PMCID: PMC10164035.
Duan H, Baratto L, Fan RE, Soerensen SJC, Liang T, Chung BI, Thong AEC, Gill H, Kunder C, Stoyanova T, Rusu M, Loening AM, Ghanouni P, Davidzon GA, Moradi F, Sonn GA, Iagaru A. Correlation of (68)Ga-RM2 PET with Postsurgery Histopathology Findings in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Cancer. J Nucl Med. 2022 Dec;63(12):1829-1835. doi: 10.2967/jnumed.122.263971. Epub 2022 May 12. PubMed PMID: 35552245.
Liu S, Alabi BR, Yin Q, Stoyanova T. Molecular mechanisms underlying the development of neuroendocrine prostate cancer. Semin Cancer Biol. 2022 Nov;86(Pt 3):57-68. doi: 10.1016/j.semcancer.2022.05.007. Epub 2022 May 18. Review. PubMed PMID: 35597438.
Alabi BR, Liu S, Stoyanova T. Current and emerging therapies for neuroendocrine prostate cancer. Pharmacol Ther. 2022 Oct;238:108255. doi: 10.1016/j.pharmthera.2022.108255. Epub 2022 Jul 26. Review. PubMed PMID: 35905791.
Wang J, Soto F, Ma P, Ahmed R, Yang H, Chen S, Wang J, Liu C, Akin D, Fu K, Cao X, Chen P, Hsu EC, Soh HT, Stoyanova T, Wu JC, Demirci U. Acoustic Fabrication of Living Cardiomyocyte-based Hybrid Biorobots. ACS Nano. 2022 Jul 26;16(7):10219-10230. doi: 10.1021/acsnano.2c01908. Epub 2022 Jun 7. PubMed PMID: 35671037.
Wang J, Soto , Liu , Yin Q, Purcell E, Zeng Y, Hsu E, Akin D, Sinclair B, Stoyanova T, Demirci . Volbots: Volvox Microalgae-Based Robots for Multimode Precision Imaging and Therapy. Advanced Functional Materials. 2022 June; 32.
Garcia-Marques F, Liu S, Totten SM, Bermudez A, Tanimoto C, Hsu EC, Nolley R, Hembree A, Stoyanova T, Brooks JD, Pitteri SJ. Protein signatures to distinguish aggressive from indolent prostate cancer. Prostate. 2022 Apr;82(5):605-616. doi: 10.1002/pros.24307. Epub 2022 Jan 31. PubMed PMID: 35098564; PubMed Central PMCID: PMC8916040.
Rice MA, Kumar V, Tailor D, Garcia-Marques FJ, Hsu EC, Liu S, Bermudez A, Kanchustambham V, Shankar V, Inde Z, Alabi BR, Muruganantham A, Shen M, Pandrala M, Nolley R, Aslan M, Ghoochani A, Agarwal A, Buckup M, Kumar M, Going CC, Peehl DM, Dixon SJ, Zare RN, Brooks JD, Pitteri SJ, Malhotra SV, Stoyanova T. SU086, an inhibitor of HSP90, impairs glycolysis and represents a treatment strategy for advanced prostate cancer. Cell Rep Med. 2022 Feb 15;3(2):100502. doi: 10.1016/j.xcrm.2021.100502. eCollection 2022 Feb 15. PubMed PMID: 35243415; PubMed Central PMCID: PMC8861828.
Liu S, Hsu EC, Shen M, Aslan M, Stoyanova T. Metastasis Model to Test the Role of Notch Signaling in Prostate Cancer. Methods Mol Biol. 2022;2472:221-233. doi: 10.1007/978-1-0716-2201-8_18. PubMed PMID: 35674904.
Guimarães CF, Ahmed R, Mataji-Kojouri A, Soto F, Wang J, Liu S, Stoyanova T, Marques AP, Reis RL, Demirci U. Engineering Polysaccharide-Based Hydrogel Photonic Constructs: From Multiscale Detection to the Biofabrication of Living Optical Fibers. Adv Mater. 2021 Dec;33(52):e2105361. doi: 10.1002/adma.202105361. Epub 2021 Oct 7. PubMed PMID: 34617338.
Aslan M, Hsu EC, Garcia-Marques FJ, Bermudez A, Liu S, Shen M, West M, Zhang CA, Rice MA, Brooks JD, West R, Pitteri SJ, Győrffy B, Stoyanova T. Oncogene-mediated metabolic gene signature predicts breast cancer outcome. NPJ Breast Cancer. 2021 Oct 28;7(1):141. doi: 10.1038/s41523-021-00341-6. PubMed PMID: 34711841; PubMed Central PMCID: PMC8553750.
Fite BZ, Hinostroza V, States L, Hicks-Nelson A, Baratto L, Kallianos K, Codari M, Yu B, Jha P, Shams M, Stoyanova T, Chapelin FF, Liu A, Rashidi A, Soto F, Quintana Y, Davidzon GA, Marycz K, Gibbs IC, Chonde DB, Patel CB, Daldrup-Link HE. Increasing Diversity in Radiology and Molecular Imaging: Current Challenges. Mol Imaging Biol. 2021 Oct;23(5):625-638. doi: 10.1007/s11307-021-01610-3. Epub 2021 Apr 26. Review. PubMed PMID: 33903986; PubMed Central PMCID: PMC8074707.
Aslan M, Hsu EC, Liu S, Stoyanova T. Quantifying the invasion and migration ability of cancer cells with a 3D Matrigel drop invasion assay. Biol Methods Protoc. 2021;6(1):bpab014. doi: 10.1093/biomethods/bpab014. eCollection 2021. PubMed PMID: 34377838; PubMed Central PMCID: PMC8346651.
Hsu EC, Shen M, Aslan M, Liu S, Kumar M, Garcia-Marques F, Nguyen HM, Nolley R, Pitteri SJ, Corey E, Brooks JD, Stoyanova T. MCM2-7 complex is a novel druggable target for neuroendocrine prostate cancer. Sci Rep. 2021 Jun 25;11(1):13305. doi: 10.1038/s41598-021-92552-x. PubMed PMID: 34172788; PubMed Central PMCID: PMC8233352.
Chen YS, Zhao Y, Beinat C, Zlitni A, Hsu EC, Chen DH, Achterberg F, Wang H, Stoyanova T, Dionne J, Gambhir SS. Ultra-high-frequency radio-frequency acoustic molecular imaging with saline nanodroplets in living subjects. Nat Nanotechnol. 2021 Jun;16(6):717-724. doi: 10.1038/s41565-021-00869-5. Epub 2021 Mar 29. PubMed PMID: 33782588; PubMed Central PMCID: PMC8454903.
Xie J, Rice MA, Chen Z, Cheng Y, Hsu EC, Chen M, Song G, Cui L, Zhou K, Castillo JB, Zhang CA, Shen B, Chin FT, Kunder CA, Brooks JD, Stoyanova T, Rao J. In Vivo Imaging of Methionine Aminopeptidase II for Prostate Cancer Risk Stratification. Cancer Res. 2021 May 1;81(9):2510-2521. doi: 10.1158/0008-5472.CAN-20-2969. Epub 2021 Feb 26. PubMed PMID: 33637565; PubMed Central PMCID: PMC8137584.
Liu S, Garcia-Marques F, Zhang CA, Lee JJ, Nolley R, Shen M, Hsu EC, Aslan M, Koul K, Pitteri SJ, Brooks JD, Stoyanova T. Discovery of CASP8 as a potential biomarker for high-risk prostate cancer through a high-multiplex immunoassay. Sci Rep. 2021 Apr 7;11(1):7612. doi: 10.1038/s41598-021-87155-5. PubMed PMID: 33828176; PubMed Central PMCID: PMC8027881.
Ghoochani A, Hsu EC, Aslan M, Rice MA, Nguyen HM, Brooks JD, Corey E, Paulmurugan R, Stoyanova T. Ferroptosis Inducers Are a Novel Therapeutic Approach for Advanced Prostate Cancer. Cancer Res. 2021 Mar 15;81(6):1583-1594. doi: 10.1158/0008-5472.CAN-20-3477. Epub 2021 Jan 22. PubMed PMID: 33483372; PubMed Central PMCID: PMC7969452.
Liu S, Shen M, Hsu EC, Zhang CA, Garcia-Marques F, Nolley R, Koul K, Rice MA, Aslan M, Pitteri SJ, Massie C, George A, Brooks JD, Gnanapragasam VJ, Stoyanova T. Discovery of PTN as a serum-based biomarker of pro-metastatic prostate cancer. Br J Cancer. 2021 Mar;124(5):896-900. doi: 10.1038/s41416-020-01200-0. Epub 2020 Dec 8. PubMed PMID: 33288843; PubMed Central PMCID: PMC7921397.
Shen M, Liu S, Stoyanova T. The role of Trop2 in prostate cancer: an oncogene, biomarker, and therapeutic target. Am J Clin Exp Urol. 2021;9(1):73-87. eCollection 2021. PubMed PMID: 33816696; PubMed Central PMCID: PMC8012837.
Tailor D, Going CC, Resendez A, Kumar V, Nambiar DK, Li Y, Dheeraj A, LaGory EL, Ghoochani A, Birk AM, Stoyanova T, Ye J, Giaccia AJ, Le QT, Singh RP, Sledge GW, Pitteri SJ, Malhotra SV. Novel Aza-podophyllotoxin derivative induces oxidative phosphorylation and cell death via AMPK activation in triple-negative breast cancer. Br J Cancer. 2021 Feb;124(3):604-615. doi: 10.1038/s41416-020-01137-4. Epub 2020 Nov 3. PubMed PMID: 33139797; PubMed Central PMCID: PMC7851402.
Buckup M, Rice MA, Hsu EC, Garcia-Marques F, Liu S, Aslan M, Bermudez A, Huang J, Pitteri SJ, Stoyanova T. Plectin is a regulator of prostate cancer growth and metastasis. Oncogene. 2021 Jan;40(3):663-676. doi: 10.1038/s41388-020-01557-9. Epub 2020 Nov 20. PubMed PMID: 33219316; PubMed Central PMCID: PMC8078627.
Li D, Liu Q, Qi Q, Shi H, Hsu EC, Chen W, Yuan W, Wu Y, Lin S, Zeng Y, Xiao Z, Xu L, Zhang Y, Stoyanova T, Jia W, Cheng Z. Gold Nanoclusters for NIR-II Fluorescence Imaging of Bones. Small. 2020 Oct;16(43):e2003851. doi: 10.1002/smll.202003851. Epub 2020 Sep 30. PubMed PMID: 33000882.
Hsu EC, Rice MA, Bermudez A, Marques FJG, Aslan M, Liu S, Ghoochani A, Zhang CA, Chen YS, Zlitni A, Kumar S, Nolley R, Habte F, Shen M, Koul K, Peehl DM, Zoubeidi A, Gambhir SS, Kunder CA, Pitteri SJ, Brooks JD, Stoyanova T. Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1. Proc Natl Acad Sci U S A. 2020 Jan 28;117(4):2032-2042. doi: 10.1073/pnas.1905384117. Epub 2020 Jan 13. PubMed PMID: 31932422; PubMed Central PMCID: PMC6994991.
Rice MA, Malhotra SV, Stoyanova T. Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer. Front Oncol. 2019;9:801. doi: 10.3389/fonc.2019.00801. eCollection 2019. Review. PubMed PMID: 31555580; PubMed Central PMCID: PMC6723105.
Rice MA, Hsu EC, Aslan M, Ghoochani A, Su A, Stoyanova T. Loss of Notch1 Activity Inhibits Prostate Cancer Growth and Metastasis and Sensitizes Prostate Cancer Cells to Antiandrogen Therapies. Mol Cancer Ther. 2019 Jul;18(7):1230-1242. doi: 10.1158/1535-7163.MCT-18-0804. Epub 2019 Apr 26. PubMed PMID: 31028097; PubMed Central PMCID: PMC7280023.
Rice MA, Stoyanova T. Biomarkers for Diagnosis and Prognosis of Prostate Cancer. Prostatectomy. 2018 November.
Going CC, Tailor D, Kumar V, Birk AM, Pandrala M, Rice MA, Stoyanova T, Malhotra S, Pitteri SJ. Quantitative Proteomic Profiling Reveals Key Pathways in the Anticancer Action of Methoxychalcone Derivatives in Triple Negative Breast Cancer. J Proteome Res. 2018 Oct 5;17(10):3574-3585. doi: 10.1021/acs.jproteome.8b00636. Epub 2018 Sep 20. PubMed PMID: 30200768; PubMed Central PMCID: PMC8078626.
Liu F, Vermesh O, Mani V, Ge TJ, Madsen SJ, Sabour A, Hsu EC, Gowrishankar G, Kanada M, Jokerst JV, Sierra RG, Chang E, Lau K, Sridhar K, Bermudez A, Pitteri SJ, Stoyanova T, Sinclair R, Nair VS, Gambhir SS, Demirci U. The Exosome Total Isolation Chip. ACS Nano. 2017 Nov 28;11(11):10712-10723. doi: 10.1021/acsnano.7b04878. Epub 2017 Nov 1. PubMed PMID: 29090896; PubMed Central PMCID: PMC5983373.
Liu X, Grogan TR, Hieronymus H, Hashimoto T, Mottahedeh J, Cheng D, Zhang L, Huang K, Stoyanova T, Park JW, Shkhyan RO, Nowroozizadeh B, Rettig MB, Sawyers CL, Elashoff D, Horvath S, Huang J, Witte ON, Goldstein AS. Low CD38 Identifies Progenitor-like Inflammation-Associated Luminal Cells that Can Initiate Human Prostate Cancer and Predict Poor Outcome. Cell Rep. 2016 Dec 6;17(10):2596-2606. doi: 10.1016/j.celrep.2016.11.010. PubMed PMID: 27926864; PubMed Central PMCID: PMC5367888.
Ju X, Jiao X, Ertel A, Casimiro MC, Di Sante G, Deng S, Li Z, Di Rocco A, Zhan T, Hawkins A, Stoyanova T, Andò S, Fatatis A, Lisanti MP, Gomella LG, Languino LR, Pestell RG. v-Src Oncogene Induces Trop2 Proteolytic Activation via Cyclin D1. Cancer Res. 2016 Nov 15;76(22):6723-6734. doi: 10.1158/0008-5472.CAN-15-3327. Epub 2016 Sep 15. PubMed PMID: 27634768; PubMed Central PMCID: PMC5330252.
Stoyanova T, Riedinger M, Lin S, Faltermeier CM, Smith BA, Zhang KX, Going CC, Goldstein AS, Lee JK, Drake JM, Rice MA, Hsu EC, Nowroozizadeh B, Castor B, Orellana SY, Blum SM, Cheng D, Pienta KJ, Reiter RE, Pitteri SJ, Huang J, Witte ON. Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer. Proc Natl Acad Sci U S A. 2016 Oct 18;113(42):E6457-E6466. doi: 10.1073/pnas.1614529113. Epub 2016 Sep 30. PubMed PMID: 27694579; PubMed Central PMCID: PMC5081658.
Drake JM, Paull EO, Graham NA, Lee JK, Smith BA, Titz B, Stoyanova T, Faltermeier CM, Uzunangelov V, Carlin DE, Fleming DT, Wong CK, Newton Y, Sudha S, Vashisht AA, Huang J, Wohlschlegel JA, Graeber TG, Witte ON, Stuart JM. Phosphoproteome Integration Reveals Patient-Specific Networks in Prostate Cancer. Cell. 2016 Aug 11;166(4):1041-1054. doi: 10.1016/j.cell.2016.07.007. Epub 2016 Aug 4. PubMed PMID: 27499020; PubMed Central PMCID: PMC4985183.
Lee JK, Phillips JW, Smith BA, Park JW, Stoyanova T, McCaffrey EF, Baertsch R, Sokolov A, Meyerowitz JG, Mathis C, Cheng D, Stuart JM, Shokat KM, Gustafson WC, Huang J, Witte ON. N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells. Cancer Cell. 2016 Apr 11;29(4):536-547. doi: 10.1016/j.ccell.2016.03.001. Epub 2016 Mar 31. PubMed PMID: 27050099; PubMed Central PMCID: PMC4829466.
Miyahira AK, Lang JM, Den RB, Garraway IP, Lotan TL, Ross AE, Stoyanova T, Cho SY, Simons JW, Pienta KJ, Soule HR. Multidisciplinary intervention of early, lethal metastatic prostate cancer: Report from the 2015 Coffey-Holden Prostate Cancer Academy Meeting. Prostate. 2016 Feb;76(2):125-39. doi: 10.1002/pros.23107. Epub 2015 Oct 19. Review. PubMed PMID: 26477609; PubMed Central PMCID: PMC5830186.
Stoyanova T, Goldstein AS. Distinct phases of human prostate cancer initiation and progression can be driven by different cell-types. Cancer Cell Microenviron. 2014;1(3). doi: 10.14800/ccm.90. PubMed PMID: 26005704; PubMed Central PMCID: PMC4441270.
Stoyanova T, Cooper AR, Drake JM, Liu X, Armstrong AJ, Pienta KJ, Zhang H, Kohn DB, Huang J, Witte ON, Goldstein AS. Prostate cancer originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells. Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20111-6. doi: 10.1073/pnas.1320565110. Epub 2013 Nov 26. PubMed PMID: 24282295; PubMed Central PMCID: PMC3864278.
Drake JM, Graham NA, Lee JK, Stoyanova T, Faltermeier CM, Sud S, Titz B, Huang J, Pienta KJ, Graeber TG, Witte ON. Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets. Proc Natl Acad Sci U S A. 2013 Dec 3;110(49):E4762-9. doi: 10.1073/pnas.1319948110. Epub 2013 Nov 18. PubMed PMID: 24248375; PubMed Central PMCID: PMC3856845.
Stoyanova TI, Goldstein AS. Identification, characterization and targeting of Docetaxel-resistant prostate cancer cells. Asian J Androl. 2013 Jan;15(1):83-4. doi: 10.1038/aja.2012.133. Epub 2012 Dec 3. PubMed PMID: 23202701; PubMed Central PMCID: PMC3739119.
Stoyanova T, Goldstein AS, Cai H, Drake JM, Huang J, Witte ON. Regulated proteolysis of Trop2 drives epithelial hyperplasia and stem cell self-renewal via β-catenin signaling. Genes Dev. 2012 Oct 15;26(20):2271-85. doi: 10.1101/gad.196451.112. PubMed PMID: 23070813; PubMed Central PMCID: PMC3475800.
Cai H, Memarzadeh S, Stoyanova T, Beharry Z, Kraft AS, Witte ON. Collaboration of Kras and androgen receptor signaling stimulates EZH2 expression and tumor-propagating cells in prostate cancer. Cancer Res. 2012 Sep 15;72(18):4672-81. doi: 10.1158/0008-5472.CAN-12-0228. Epub 2012 Jul 17. PubMed PMID: 22805308; PubMed Central PMCID: PMC3445707.
Drake JM, Graham NA, Stoyanova T, Sedghi A, Goldstein AS, Cai H, Smith DA, Zhang H, Komisopoulou E, Huang J, Graeber TG, Witte ON. Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression. Proc Natl Acad Sci U S A. 2012 Jan 31;109(5):1643-8. doi: 10.1073/pnas.1120985109. Epub 2012 Jan 17. PubMed PMID: 22307624; PubMed Central PMCID: PMC3277127.
Stoyanova T, Roy N, Bhattacharjee S, Kopanja D, Valli T, Bagchi S, Raychaudhuri P. p21 cooperates with DDB2 protein in suppression of ultraviolet ray-induced skin malignancies. J Biol Chem. 2012 Jan 27;287(5):3019-28. doi: 10.1074/jbc.M111.295816. Epub 2011 Dec 13. PubMed PMID: 22167187; PubMed Central PMCID: PMC3270959.
Kopanja D, Roy N, Stoyanova T, Hess RA, Bagchi S, Raychaudhuri P. Cul4A is essential for spermatogenesis and male fertility. Dev Biol. 2011 Apr 15;352(2):278-87. doi: 10.1016/j.ydbio.2011.01.028. Epub 2011 Feb 1. PubMed PMID: 21291880; PubMed Central PMCID: PMC3065526.
What would you like to do?